The clinical study is a prospective, multi-center, non-randomized, single-arm study designed to assess the safety and effectiveness of the GORE EXCLUDER iliac branch endoprosthesis for treatment of patients with common iliac artery aneurysms (CIAA) or aorto-iliac aneurysms (AIA).
The patient was treated at St. Anthony’s Medical Center, in St. Louis, Missouri.
The GORE EXCLUDER iliac branch devices (iliac branch component and internal iliac component) are used in conjunction with the GORE EXCLUDER AAA endoprosthesis to isolate the common iliac artery from systemic blood flow and preserve blood flow in the external iliac and internal iliac arteries.
Gore aortic business unit leader Ryan Takeuchi noted providing the best possible patient care and fulfilling unmet clinical needs require constant innovation.
"Gore is committed to advancing these innovations through collaboration with the clinical community. We are excited that endovascular specialists globally are expressing such a high level of interest in the study and in iliac artery repair solutions," Takeuchi added.
Endovascular specialists will enroll 60 patients at up to 50 sites during the course of this study. The GORE EXCLUDER iliac branch endoprosthesis received CE Mark in October 2013 and is currently available in the US for investigational purposes only.
